logo
welcome
Ars Technica

Ars Technica

Eli Lilly raises price of Zepbound while trumpeting discount on starter vials

Ars Technica
Summary
Nutrition label

76% Informative

Eli Lilly announced Tuesday that it is now selling starter dosages of its weight-loss drug tirzepatide ( Zepbound ) at a price significantly lower than before.

But critics quickly noticed that the company also quietly raised the price on current versions of the drug.

In the past, Lilly sold Zepbound only in injectable pens with a list price of $ 1,060 for a month 's supply.

VR Score

76

Informative language

75

Neutral language

7

Article tone

semi-formal

Language

English

Language complexity

39

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links